In atopic dermatitis models, oral Rh1 administration at 20 mg/kg promoted a regulatory phenotype by increasing forkhead box P3 (Foxp3) mRNA expression in draining lymph nodes while decreasing IL-4 expression, suggesting dual action through both Th2 suppression and regulatory T cell enhancement. This evidence concerns the gene FOXP3 and atopic eczema.